Technology Assessment: Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy, Part 1. Table 11

You Are Here: AHRQ Archive Home > Technology Assessment Archive > Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 11. Summary of Survival in Second-line (or Higher) Treatment With Cytotoxic Chemotherapy for Advanced NSCLC

Study ID	Diagnosis (no. of patients)	Sub-groups	Survival from Start of Treatment			Progression-free Survival
Study ID	Diagnosis (no. of patients)	Sub-groups	Median (months)	1-year (%)	HR (95% CI) [p-value]	Median TTP (months)	1-year (%)	HR (95% CI) [p-value]
Phase III
Shepherd, et al., 2000³³	NSCLC (204)	BSC Docetaxel 75 mg/m² Docetaxel 100 mg/m²	4.6 7.5 5.9	- - - - - -	p = 0.010 p = 0.047	- - - - - -	- - - - - -	- - - -
Fossella, et al., 2000³⁴	NSCLC (358)	Vinorelbine 30 mg/m² or ifosfamide 2 mg/m² Docetaxel 75 mg/m² Docetaxel 100 mg/m²	5.4 5.8 6.6	10 32 32	p = 0.001 p = 0.002	7.9 ^b 8.5 ^b 8.4 ^b	- - - - - -	p = 0.093 p = 0.046
Hanna, et al., 2004³²	NSCLC (571)	Pemetrexed 500 mg/m² Docetaxel 75 mg/m²	8.3 7.9	30 30	0.99	2.9 2.9	- - - -	0.97 [p = 0.76]
Retrospective
Massarelli, et al., 2003³⁵	NSCLC 43 pts 14 pts	Various regimens 3rd line 4th line	5.4 5.9	- - - -	- - - -	- - - -	- - - -	- -

^b Fossella, et al., (2000)³⁴ reported time to progression (TTP) in patients who were censored at the time of administration of subsequent therapy, which is why the TTP is longer than median survival.

Abbreviations: BSC = best supportive care; CI = confidence interval; HR = hazard ratio; no. = number; NR = not reported; NSCLS = non-small cell lung cancer; TTP = time to progression.

Return to Document

The information on this page is archived and provided for reference purposes only.